Expression of oncology targets in healthy biliary tract tissue samples
Research type
Research Study
Full title
Expression of oncology targets in healthy biliary tract tissue samples
IRAS ID
312336
Contact name
Gayle Marshall
Contact email
Sponsor organisation
RedX Pharma
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
Medicines Discovery Catapult (MDC) are currently investigating the expression of various oncology targets/biomarkers within human biliary tract cancer samples, with a view to developing a patient selection approach for more effective treatment of these cancers. The proposed study would support this work, by assessing expression of the same oncology targets / biomarkers within healthy biliary tissue samples.
MDC are looking to access human healthy biliary tract tissue samples through commercially available biobanks. This work will involve analysis on the Nanostring nCounter platform, immunohistochemistry, mass spectroscopy, transcriptomic analysis and microscopy to detect the targets of interest within the samples.
REC name
London - Riverside Research Ethics Committee
REC reference
22/PR/1367
Date of REC Opinion
26 Oct 2022
REC opinion
Favourable Opinion